Dose-dependent Induction of Cytochrome P450 (CYP) 3A4 and Activation of Pregnane X Receptor by Topiramate

Epilepsia

Volumn 44, Issue 12, 2003, Pages 1521-1528

  Nallani, Srikanth C ^a   Glauser, Tracy A ^b   Hariparsad, Niresh ^a   Setchell, Kenneth ^b   Buckley, Donna J ^a   Buckley, Arthur R ^a   Desai, Pankaj B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

CYP3A4; Enzyme; Hepatocytes; hPXR; Induction; Topiramate

Indexed keywords

CYTOCHROME P450 3A4; ETHINYLESTRADIOL; MESSENGER RNA; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; TOPIRAMATE;

ADULT; AGED; ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER CELL; MALE; PRIORITY JOURNAL; REACTION TIME; REPORTER GENE; WESTERN BLOTTING;

ANIMALS; ANTICONVULSANTS; CELL LINE; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FRUCTOSE; HEPATOCYTES; HUMANS; PHENOBARBITAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RIFAMPIN; RNA, MESSENGER; TESTOSTERONE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0346103737     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2003.06203.x     Document Type: Article

References (30)

1. Glauser TA. Topiramate. In: Pellock JA, Dodson WE, Bourgeois BFD, eds. Pediatric epilepsy: diagnosis and therapy. New York: Demos Medical Publishing, 2001:475-88.
2. Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-23.
3. Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003;44:540-9.
4. Wrighton SA, Thummel KE. CYP3A. In: Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000:115-33.
5. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23.
6. Blumberg B, Sabbagh W, Jr., Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12:3195-205.
7. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002;30:608-12.
8. Kostrubsky VE, Lewis LD, Strom SC, et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998;355:131-6.
9. Kostrubsky VE, Ramachandran V, Venkataramanan R, et al. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 1999;27:887-94.
10. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001;48:115-22.
11. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
12. Waxman DJ, Ko A, Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem 1983;258:11937-47.
13. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991-5.
14. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-33.
15. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate: a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91.
16. Lindberger M, Tomson T, Ohman I, et al. Estimation of topiramate in subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma: a single case microdialysis study. Epilepsia 1999;40:800-2.
17. Topamax (topiramate product monograph). 2002.
18. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002;72:1-9.
19. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
20. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 2001;29:1205-9.
21. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998;95:12208-13.
22. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292:2329-33.
23. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39.
24. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14:3014-23.
25. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275:15122-7.
26. Tzameli I, Pissios P, Schuetz EG, et al. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 2000;20:2951-8.
27. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002:30:795-804.
28. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S14-7.
29. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-95.
30. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001;29:242-51.